Dr Alvin Fox
University of Texas Health Science Center, Dallas
Univesity of North Carolina School of Medicine
Ph.D. University of Leeds
Office: (803) 216-3409
Fax: (803) 216-3428
Search PubMed for publications by Dr Alvin Fox
Our research interest relates to biodefense and homeland security encompassing proteomics. We are developing a novel anthrax vaccine funded by NIH. A carbohydrate was discovered, by our group, which surrounds the spore of Bacillus anthracis that was subsequently shown to be a component of two glycoproteins. These glycoproteins are serving as the focus for our vaccine studies. The spore is the infective agent and thus the earliest stage of the disease process is being targeted. The current US anthrax vaccine for human use involves a later stage of the disease, when the dormant spore has germinated into a vegetative form, and produced a life-threatening lethal toxin. Other interests are in the area of diagnostics relating to biodetection (rapid detection of a biological warfare attack) and forensics (source verification, e.g. the Amerithrax attacks on the US postal service). Dr. Fox is the Editor-in-Chief of the Journal of Microbiological Methods, joint-Editor-in-Chief of Molecular and Cellular Probes and is on the Editorial board of the Journal of Clinical Microbiology.